X4制药公司近日宣布,其创新药物Xolremdi®(Mavorixafor)已获得欧盟委员会的正式批准。这一突破性疗法成为欧盟区域内首个且目前唯一获批用于治疗WHIM综合征患者的治疗方案,标志着罕见病治疗领域的重要进展。
X4制药公司近日宣布,其创新药物Xolremdi®(Mavorixafor)已获得欧盟委员会的正式批准。这一突破性疗法成为欧盟区域内首个且目前唯一获批用于治疗WHIM综合征患者的治疗方案,标志着罕见病治疗领域的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.